Jessica Hergert | Authors


In Unresectable Stage III NSCLC, Real-World PFS Benefit Reported With PACIFIC Regimen

September 21, 2021

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.